442 related articles for article (PubMed ID: 26485309)
21. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.
Thomson SB; Stam A; Brouwers C; Fodale V; Bresciani A; Vermeulen M; Mostafavi S; Petkau TL; Hill A; Yung A; Russell-Schulz B; Kozlowski P; MacKay A; Ma D; Beg MF; Evers MM; Vallès A; Leavitt BR
Brain; 2023 Jun; 146(6):2298-2315. PubMed ID: 36508327
[TBL] [Abstract][Full Text] [Related]
22. A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity.
Yao Y; Cui X; Al-Ramahi I; Sun X; Li B; Hou J; Difiglia M; Palacino J; Wu ZY; Ma L; Botas J; Lu B
Elife; 2015 Mar; 4():. PubMed ID: 25738228
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
[TBL] [Abstract][Full Text] [Related]
24. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
Stanek LM; Bu J; Shihabuddin LS
Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
[TBL] [Abstract][Full Text] [Related]
25. Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models.
Franich NR; Basso M; André EA; Ochaba J; Kumar A; Thein S; Fote G; Kachemov M; Lau AL; Yeung SY; Osmand A; Zeitlin SO; Ratan RR; Thompson LM; Steffan JS
J Huntingtons Dis; 2018; 7(2):137-150. PubMed ID: 29843246
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
27. Maintenance of basal levels of autophagy in Huntington's disease mouse models displaying metabolic dysfunction.
Baldo B; Soylu R; Petersén A
PLoS One; 2013; 8(12):e83050. PubMed ID: 24376631
[TBL] [Abstract][Full Text] [Related]
28. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.
Jia H; Kast RJ; Steffan JS; Thomas EA
Hum Mol Genet; 2012 Dec; 21(24):5280-93. PubMed ID: 22965876
[TBL] [Abstract][Full Text] [Related]
29. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
30. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
31. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
[TBL] [Abstract][Full Text] [Related]
32. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease.
Menalled L; Zanjani H; MacKenzie L; Koppel A; Carpenter E; Zeitlin S; Chesselet MF
Exp Neurol; 2000 Apr; 162(2):328-42. PubMed ID: 10739639
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.
Jiang M; Wang J; Fu J; Du L; Jeong H; West T; Xiang L; Peng Q; Hou Z; Cai H; Seredenina T; Arbez N; Zhu S; Sommers K; Qian J; Zhang J; Mori S; Yang XW; Tamashiro KL; Aja S; Moran TH; Luthi-Carter R; Martin B; Maudsley S; Mattson MP; Cichewicz RH; Ross CA; Holtzman DM; Krainc D; Duan W
Nat Med; 2011 Dec; 18(1):153-8. PubMed ID: 22179319
[TBL] [Abstract][Full Text] [Related]
35. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
[TBL] [Abstract][Full Text] [Related]
36. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
[TBL] [Abstract][Full Text] [Related]
37. CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease.
Crittenden JR; Dunn DE; Merali FI; Woodman B; Yim M; Borkowska AE; Frosch MP; Bates GP; Housman DE; Lo DC; Graybiel AM
Hum Mol Genet; 2010 May; 19(9):1756-65. PubMed ID: 20147317
[TBL] [Abstract][Full Text] [Related]
38. Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells.
Ribeiro M; Rosenstock TR; Cunha-Oliveira T; Ferreira IL; Oliveira CR; Rego AC
Free Radic Biol Med; 2012 Nov; 53(10):1857-67. PubMed ID: 22982598
[TBL] [Abstract][Full Text] [Related]
39. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Rogers DA; Bissada N; Vogl AW; Hayden MR; Leavitt BR
Hum Mol Genet; 2005 May; 14(10):1379-92. PubMed ID: 15829505
[TBL] [Abstract][Full Text] [Related]
40. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
